Induction by verapamil of a rapid increase in ATP consumption in multidrug-resistant tumor cells. 1988

H J Broxterman, and H M Pinedo, and C M Kuiper, and L C Kaptein, and G J Schuurhuis, and J Lankelma
Department of Oncology, Free University Hospital, Amsterdam, The Netherlands.

A marked increase in cellular ATP consumption was induced by verapamil in the multidrug-resistant (MDR) cell line 2780AD, but not in the drug-sensitive parental cell line A2780. A group of structurally unrelated drugs in concentrations known to reverse MDR, but not the verapamil analog tiapamil, a weak modulator of MDR, had similar effects. This effect was saturated at verapamil concentrations of about 1 microM. These data demonstrate that verapamil concentrations in MDR cells are maintained at a low level at the expense of ATP hydrolysis, and provide a first indication of the amount of metabolic energy used in this process.

UI MeSH Term Description Entries
D009994 Osmolar Concentration The concentration of osmotically active particles in solution expressed in terms of osmoles of solute per liter of solution. Osmolality is expressed in terms of osmoles of solute per kilogram of solvent. Ionic Strength,Osmolality,Osmolarity,Concentration, Osmolar,Concentrations, Osmolar,Ionic Strengths,Osmolalities,Osmolar Concentrations,Osmolarities,Strength, Ionic,Strengths, Ionic
D010051 Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS. Cancer of Ovary,Ovarian Cancer,Cancer of the Ovary,Neoplasms, Ovarian,Ovary Cancer,Ovary Neoplasms,Cancer, Ovarian,Cancer, Ovary,Cancers, Ovarian,Cancers, Ovary,Neoplasm, Ovarian,Neoplasm, Ovary,Neoplasms, Ovary,Ovarian Cancers,Ovarian Neoplasm,Ovary Cancers,Ovary Neoplasm
D010641 Phenotype The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment. Phenotypes
D003630 Daunorubicin A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of LEUKEMIA and other NEOPLASMS. Daunomycin,Rubidomycin,Rubomycin,Cerubidine,Dauno-Rubidomycine,Daunoblastin,Daunoblastine,Daunorubicin Hydrochloride,NSC-82151,Dauno Rubidomycine,Hydrochloride, Daunorubicin,NSC 82151,NSC82151
D004351 Drug Resistance Diminished or failed response of an organism, disease or tissue to the intended effectiveness of a chemical or drug. It should be differentiated from DRUG TOLERANCE which is the progressive diminution of the susceptibility of a human or animal to the effects of a drug, as a result of continued administration. Resistance, Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006868 Hydrolysis The process of cleaving a chemical compound by the addition of a molecule of water.
D000255 Adenosine Triphosphate An adenine nucleotide containing three phosphate groups esterified to the sugar moiety. In addition to its crucial roles in metabolism adenosine triphosphate is a neurotransmitter. ATP,Adenosine Triphosphate, Calcium Salt,Adenosine Triphosphate, Chromium Salt,Adenosine Triphosphate, Magnesium Salt,Adenosine Triphosphate, Manganese Salt,Adenylpyrophosphate,CaATP,CrATP,Manganese Adenosine Triphosphate,MgATP,MnATP,ATP-MgCl2,Adenosine Triphosphate, Chromium Ammonium Salt,Adenosine Triphosphate, Magnesium Chloride,Atriphos,Chromium Adenosine Triphosphate,Cr(H2O)4 ATP,Magnesium Adenosine Triphosphate,Striadyne,ATP MgCl2
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

H J Broxterman, and H M Pinedo, and C M Kuiper, and L C Kaptein, and G J Schuurhuis, and J Lankelma
October 1989, Journal of the National Cancer Institute,
H J Broxterman, and H M Pinedo, and C M Kuiper, and L C Kaptein, and G J Schuurhuis, and J Lankelma
April 1995, Biochemical and biophysical research communications,
H J Broxterman, and H M Pinedo, and C M Kuiper, and L C Kaptein, and G J Schuurhuis, and J Lankelma
May 1989, Journal of the National Cancer Institute,
H J Broxterman, and H M Pinedo, and C M Kuiper, and L C Kaptein, and G J Schuurhuis, and J Lankelma
June 1989, Biochemical and biophysical research communications,
H J Broxterman, and H M Pinedo, and C M Kuiper, and L C Kaptein, and G J Schuurhuis, and J Lankelma
October 2000, The Journal of antibiotics,
H J Broxterman, and H M Pinedo, and C M Kuiper, and L C Kaptein, and G J Schuurhuis, and J Lankelma
August 1988, Cancer research,
H J Broxterman, and H M Pinedo, and C M Kuiper, and L C Kaptein, and G J Schuurhuis, and J Lankelma
September 1992, Cancer research,
H J Broxterman, and H M Pinedo, and C M Kuiper, and L C Kaptein, and G J Schuurhuis, and J Lankelma
January 2018, Pharmaceutical nanotechnology,
H J Broxterman, and H M Pinedo, and C M Kuiper, and L C Kaptein, and G J Schuurhuis, and J Lankelma
January 1990, Cancer chemotherapy and pharmacology,
H J Broxterman, and H M Pinedo, and C M Kuiper, and L C Kaptein, and G J Schuurhuis, and J Lankelma
January 2018, Scientific reports,
Copied contents to your clipboard!